AAPL344.66+5.16 (+1.52%) ▲|ABBV283.42-5.66 (-1.96%) ▼|ABT98.57-3.89 (-3.79%) ▼|ACN237.60-1.53 (-0.64%) ▼|ADBE255.28-1.45 (-0.56%) ▼|AMAT409.14+4.16 (+1.03%) ▲|AMD553.81+19.07 (+3.57%) ▲|AMGN437.33-1.61 (-0.37%) ▼|AMT178.95-4.61 (-2.51%) ▼|AMZN263.93+1.30 (+0.50%) ▲|AVGO338.58+4.21 (+1.26%) ▲|AXP323.66+5.32 (+1.67%) ▲|BA192.56+2.09 (+1.10%) ▲|BAC50.94+0.30 (+0.59%) ▲|BKNG158.82-5.10 (-3.11%) ▼|BLK1,142.09+13.41 (+1.19%) ▲|BMY60.82-0.87 (-1.40%) ▼|BNY146.54+2.29 (+1.59%) ▲|BRK-B542.08+2.26 (+0.42%) ▲|C123.61+1.10 (+0.90%) ▲|CAT741.55+16.31 (+2.25%) ▲|CL93.71-0.83 (-0.88%) ▼|CMCSA21.89-0.47 (-2.10%) ▼|COF208.30+6.74 (+3.34%) ▲|COP145.86-0.09 (-0.06%) ▼|COST996.30+1.69 (+0.17%) ▲|CRM242.29-0.14 (-0.06%) ▼|CSCO107.43+0.72 (+0.67%) ▲|CVS94.31-0.44 (-0.46%) ▼|CVX226.55+0.84 (+0.37%) ▲|DE632.65+0.45 (+0.07%) ▲|DHR230.57+6.33 (+2.82%) ▲|DIS111.38-0.29 (-0.26%) ▼|DUK121.06-0.28 (-0.23%) ▼|EMR164.95+4.49 (+2.80%) ▲|FDX299.55+0.79 (+0.26%) ▲|GD345.72+1.28 (+0.37%) ▲|GE298.48-1.39 (-0.46%) ▼|GEV928.88+38.55 (+4.33%) ▲|GILD153.46-3.05 (-1.95%) ▼|GM76.15-0.94 (-1.22%) ▼|GOOG330.45-5.95 (-1.77%) ▼|GOOGL334.59-5.69 (-1.67%) ▼|GS903.89+19.08 (+2.16%) ▲|HD314.43-0.68 (-0.22%) ▼|HON215.44+2.12 (+0.99%) ▲|IBM245.41+3.49 (+1.44%) ▲|INTC92.64+0.95 (+1.03%) ▲|INTU334.16-1.13 (-0.34%) ▼|ISRG429.84-8.16 (-1.86%) ▼|JNJ255.99-3.37 (-1.30%) ▼|JPM334.50-0.76 (-0.23%) ▼|KO92.67-0.82 (-0.88%) ▼|LIN502.06+0.17 (+0.03%) ▲|LLY1,270.37-13.29 (-1.04%) ▼|LMT548.75+0.04 (+0.01%) ▲|LOW196.54-0.75 (-0.38%) ▼|LRCX261.42-2.03 (-0.77%) ▼|MA623.34+2.92 (+0.47%) ▲|MCD245.86-0.66 (-0.27%) ▼|MDLZ62.47-1.53 (-2.38%) ▼|MDT93.52-1.11 (-1.17%) ▼|META707.79+13.54 (+1.95%) ▲|MMM174.01+2.64 (+1.54%) ▲|MO73.86-0.78 (-1.05%) ▼|MRK148.63+0.33 (+0.22%) ▲|MS184.97+4.57 (+2.53%) ▲|MSFT532.64+0.77 (+0.14%) ▲|MU917.85+21.78 (+2.43%) ▲|NEE78.69-0.18 (-0.22%) ▼|NFLX65.71-2.98 (-4.34%) ▼|NKE37.80-0.09 (-0.22%) ▼|NOW152.96+3.42 (+2.28%) ▲|NVDA221.37+4.90 (+2.26%) ▲|ORCL129.92-1.22 (-0.93%) ▼|PEP134.62+0.60 (+0.44%) ▲|PFE29.72-0.40 (-1.31%) ▼|PG157.73-1.59 (-1.00%) ▼|PLTR199.52+6.92 (+3.59%) ▲|PM196.84-3.07 (-1.53%) ▼|QCOM177.67+1.96 (+1.12%) ▲|RTX189.66-3.68 (-1.90%) ▼|SBUX98.74-0.64 (-0.64%) ▼|SCHW91.69+0.80 (+0.88%) ▲|SO90.53-0.18 (-0.20%) ▼|SPG206.14-0.85 (-0.41%) ▼|T21.96-1.46 (-6.23%) ▼|TMO694.24+6.87 (+1.00%) ▲|TMUS153.10-4.65 (-2.95%) ▼|TSLA386.45+12.74 (+3.41%) ▲|TXN288.23+10.45 (+3.76%) ▲|UBER68.23-0.72 (-1.04%) ▼|UNH417.32-1.94 (-0.46%) ▼|UNP289.18+1.57 (+0.55%) ▲|UPS100.18+1.66 (+1.68%) ▲|USB59.35+0.26 (+0.44%) ▲|V408.62+2.05 (+0.50%) ▲|VZ43.48-1.07 (-2.39%) ▼|WFC82.31+0.11 (+0.13%) ▲|WMT117.74-0.11 (-0.09%) ▼|XOM177.70-0.17 (-0.09%) ▼|AAPL344.66+5.16 (+1.52%) ▲|ABBV283.42-5.66 (-1.96%) ▼|ABT98.57-3.89 (-3.79%) ▼|ACN237.60-1.53 (-0.64%) ▼|ADBE255.28-1.45 (-0.56%) ▼|AMAT409.14+4.16 (+1.03%) ▲|AMD553.81+19.07 (+3.57%) ▲|AMGN437.33-1.61 (-0.37%) ▼|AMT178.95-4.61 (-2.51%) ▼|AMZN263.93+1.30 (+0.50%) ▲|AVGO338.58+4.21 (+1.26%) ▲|AXP323.66+5.32 (+1.67%) ▲|BA192.56+2.09 (+1.10%) ▲|BAC50.94+0.30 (+0.59%) ▲|BKNG158.82-5.10 (-3.11%) ▼|BLK1,142.09+13.41 (+1.19%) ▲|BMY60.82-0.87 (-1.40%) ▼|BNY146.54+2.29 (+1.59%) ▲|BRK-B542.08+2.26 (+0.42%) ▲|C123.61+1.10 (+0.90%) ▲|CAT741.55+16.31 (+2.25%) ▲|CL93.71-0.83 (-0.88%) ▼|CMCSA21.89-0.47 (-2.10%) ▼|COF208.30+6.74 (+3.34%) ▲|COP145.86-0.09 (-0.06%) ▼|COST996.30+1.69 (+0.17%) ▲|CRM242.29-0.14 (-0.06%) ▼|CSCO107.43+0.72 (+0.67%) ▲|CVS94.31-0.44 (-0.46%) ▼|CVX226.55+0.84 (+0.37%) ▲|DE632.65+0.45 (+0.07%) ▲|DHR230.57+6.33 (+2.82%) ▲|DIS111.38-0.29 (-0.26%) ▼|DUK121.06-0.28 (-0.23%) ▼|EMR164.95+4.49 (+2.80%) ▲|FDX299.55+0.79 (+0.26%) ▲|GD345.72+1.28 (+0.37%) ▲|GE298.48-1.39 (-0.46%) ▼|GEV928.88+38.55 (+4.33%) ▲|GILD153.46-3.05 (-1.95%) ▼|GM76.15-0.94 (-1.22%) ▼|GOOG330.45-5.95 (-1.77%) ▼|GOOGL334.59-5.69 (-1.67%) ▼|GS903.89+19.08 (+2.16%) ▲|HD314.43-0.68 (-0.22%) ▼|HON215.44+2.12 (+0.99%) ▲|IBM245.41+3.49 (+1.44%) ▲|INTC92.64+0.95 (+1.03%) ▲|INTU334.16-1.13 (-0.34%) ▼|ISRG429.84-8.16 (-1.86%) ▼|JNJ255.99-3.37 (-1.30%) ▼|JPM334.50-0.76 (-0.23%) ▼|KO92.67-0.82 (-0.88%) ▼|LIN502.06+0.17 (+0.03%) ▲|LLY1,270.37-13.29 (-1.04%) ▼|LMT548.75+0.04 (+0.01%) ▲|LOW196.54-0.75 (-0.38%) ▼|LRCX261.42-2.03 (-0.77%) ▼|MA623.34+2.92 (+0.47%) ▲|MCD245.86-0.66 (-0.27%) ▼|MDLZ62.47-1.53 (-2.38%) ▼|MDT93.52-1.11 (-1.17%) ▼|META707.79+13.54 (+1.95%) ▲|MMM174.01+2.64 (+1.54%) ▲|MO73.86-0.78 (-1.05%) ▼|MRK148.63+0.33 (+0.22%) ▲|MS184.97+4.57 (+2.53%) ▲|MSFT532.64+0.77 (+0.14%) ▲|MU917.85+21.78 (+2.43%) ▲|NEE78.69-0.18 (-0.22%) ▼|NFLX65.71-2.98 (-4.34%) ▼|NKE37.80-0.09 (-0.22%) ▼|NOW152.96+3.42 (+2.28%) ▲|NVDA221.37+4.90 (+2.26%) ▲|ORCL129.92-1.22 (-0.93%) ▼|PEP134.62+0.60 (+0.44%) ▲|PFE29.72-0.40 (-1.31%) ▼|PG157.73-1.59 (-1.00%) ▼|PLTR199.52+6.92 (+3.59%) ▲|PM196.84-3.07 (-1.53%) ▼|QCOM177.67+1.96 (+1.12%) ▲|RTX189.66-3.68 (-1.90%) ▼|SBUX98.74-0.64 (-0.64%) ▼|SCHW91.69+0.80 (+0.88%) ▲|SO90.53-0.18 (-0.20%) ▼|SPG206.14-0.85 (-0.41%) ▼|T21.96-1.46 (-6.23%) ▼|TMO694.24+6.87 (+1.00%) ▲|TMUS153.10-4.65 (-2.95%) ▼|TSLA386.45+12.74 (+3.41%) ▲|TXN288.23+10.45 (+3.76%) ▲|UBER68.23-0.72 (-1.04%) ▼|UNH417.32-1.94 (-0.46%) ▼|UNP289.18+1.57 (+0.55%) ▲|UPS100.18+1.66 (+1.68%) ▲|USB59.35+0.26 (+0.44%) ▲|V408.62+2.05 (+0.50%) ▲|VZ43.48-1.07 (-2.39%) ▼|WFC82.31+0.11 (+0.13%) ▲|WMT117.74-0.11 (-0.09%) ▼|XOM177.70-0.17 (-0.09%) ▼|
14.6 C
New York
Wednesday, October 21, 2026

Tag: pharmaceutical products

newsFORsourcecompanycontentinformation1releasesmarket

HLS Therapeutics Announces Q2 2025 Financial Results

Adjusted EBITDA grew 21% in Q2 and 29% year-to-date Cash from operations grew 83% in Q2 and 147% year-to-dateMade principal repayments on the Company's...

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the Taiwan Food and Drug Administration for the Treatment of Moderately to...

SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing...

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update

Woburn, MA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, today reported financial results for the three and six months ended June 30, 2025 and provided a business update.

MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States

MediPharm Labs holds unique US Food and Drug Administration (FDA) site registration in relation to the manufacturing and release of pharmaceutical cannabis products.  MediPharm...

Everest Medicines to Announce 2025 Interim Results on August 29, 2025

SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and...

Everest Medicines to Announce 2025 Interim Results on August 29, 2025

SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and...

Everest Medicines Announces Full Approval of NEFECON® in Taiwan

SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

Vitiligo Market to Register Incremental Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

The vitiligo market is witnessing steady growth due to rising disease awareness, improved diagnostic capabilities, and advancements in treatment options such as JAK inhibitors...

LSL PHARMA GROUP ANNOUNCES THE COMPLETION OF EARLY REDEMPTION OF ALL 11% UNSECURED CONVERTIBLE DEBENTURES

BOUCHERVILLE, QC, Aug. 4, 2025 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) ("LSL Pharma" or the "Corporation"), a Canadian integrated pharmaceutical company, today announced...

Zenara Pharma Receives U.S. FDA Approval for First Generic of Sertraline Hydrochloride Capsules with 180-Day CGT Exclusivity

HYDERABAD, India, August 1, 2025 /PRNewswire/ -- Zenara Pharma Private Limited ("Zenara"), a Biophore company, today announced that it has received final approval from the U.S....

Zenara Pharma Receives U.S. FDA Approval for First Generic of Sertraline Hydrochloride Capsules with 180-Day CGT Exclusivity

HYDERABAD, India, July 31, 2025 /PRNewswire/ -- Zenara Pharma Private Limited ("Zenara"), a Biophore company, today announced that it has received final approval from the U.S....

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil

MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular lymphoma (FL). The supplemental application for the additional indication was selected for review under Project Orbis.

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: 

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPharmaceutical products

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers